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Introduction {#s1}
============

Tetrabromobisphenol A (TBBPA; CAS 79-94-7) is the most-produced flame retardant, with global use over $170,000\,\text{metric}\,\text{tons}/y$ ([@c23]). Approximately 80% of TBBPA is used in reactive applications, where it is covalently bound to the polymer of epoxy resins for printed circuit boards in electronics equipment ([@c14]; [@c80]). The remaining 20% of TBBPA is used in additive applications, where it is physically blended with rather than chemically bound to the polymer, as in plastic housing for electronics equipment ([@c14]; [@c80]). Both reactive- and additive-treated products release TBBPA into the environment ([@c55]; [@c80]). TBBPA has been detected in soil and sediment ([@c53]; [@c86]; [@c99]), surface and waste water ([@c45]; [@c94]), and air and indoor dust ([@c50]; [@c64]; [@c89]; [@c93]). Nonoccupational TBBPA exposure in humans occurs via inhalation and ingestion of dust, as well as through dermal contact with dust and free (unreacted) TBBPA in consumer products ([@c2]; [@c46]). TBBPA is bioavailable in humans, as shown by its detection in human serum ([@c13]; [@c25]), plasma ([@c33]), breast milk ([@c1]; [@c25]; [@c63]), and adipose tissue ([@c13]; [@c41]).

The potential for TBBPA to act as an endocrine-disrupting chemical is not well understood. Mechanisms of endocrine disruption by TBBPA could include actions on estrogen, androgen, glucocorticoid, or thyroid hormone receptors, or combinations of any or all of these receptors ([@c4]; [@c29]; [@c36]). Considering evidence of estrogenic actions, some studies found that TBBPA binds to estrogen receptor (ER) $\alpha$ in *in vitro* assays ([@c54]; [@c67]; [@c83]), whereas other studies found that TBBPA failed to bind $\text{ER}\alpha$ in *in vitro* assays ([@c20]; [@c29]; [@c52]; [@c56]; [@c58]; [@c61]; [@c75], [@c76]) and in molecular modeling studies ([@c100]). More recent work has examined indirect mechanisms of estrogenicity whereby TBBPA disrupts estrogen homeostasis ([@c35]; [@c51]; [@c78]; [@c91]). One proposed mechanism is that TBBPA inhibits the metabolism of $17\beta - \text{estradiol}$ (E2), thus increasing its bioavailability, via interactions with conjugating enzymes ([@c51]; [@c78]; [@c91]). These enzymes include estrogen sulfotransferase (SULT), UDP-glucuronosyltransferase (UGT), cytochrome p450 (CYP), and $17\beta - \text{hydroxysteroid}$ dehydrogenase ($17\beta - \text{HSD}$) ([@c21]; [@c91]). Another proposed mechanism is that TBBPA enhances E2 secretion via actions on aromatase (CYP19) expression ([@c35]).

We previously demonstrated *in vivo* interactions among bisphenol A (BPA), E2, and triclosan (CAS 3,380-34-5), an antimicrobial agent found in soaps and cosmetics. Compared with vehicle-treated animals, male and female mice given a single dose of $0.6–18\;{mg}$ triclosan showed greater concentrations of ${}^{14}C - \text{BPA}$ in blood serum and in reproductive and other tissues ([@c72]). Similarly, female mice given a single dose of $1–2\;{mg}$ triclosan showed greater concentrations of exogenous ${}^{3}H - \text{E2}$ in the uterus and natural E2 in urine than did vehicle-treated animals ([@c71]). Blastocyst implantation in inseminated female mice can be disrupted by high doses of BPA ([@c7], [@c8], [@c6]; [@c10]) and triclosan ([@c16]); lower doses of each substance that were insufficient on their own disrupted implantation when combined ([@c16]). Whereas triclosan alone was ineffective in a uterotrophic assay of weanling rats, elevated uterine weight occurred following concurrent triclosan and ethinyl estradiol exposure ([@c82]). These findings are consistent with evidence that triclosan is conjugated by SULT, UGT, and CYP ([@c92]) and that it can inhibit the activity of SULT and UGT toward other substances, including BPA and E2 ([@c40], [@c39]; [@c87]).

Because humans are routinely exposed to multiple potential endocrine-disrupting chemicals, it is important to investigate these chemicals' capacity to interact with each other and with endogenous steroids *in vivo*. Here, we undertook to measure the interactions of TBBPA, triclosan, and BPA. Whereas evidence of direct ER activation by TBBPA and triclosan is weak, BPA is a more established environmental estrogen ([@c77]; [@c79]; [@c101]). Based on the proposed disruption of estrogen homeostasis via inhibitory actions of TBBPA on conjugating enzyme activity ([@c51]; [@c78]; [@c91]), we hypothesized that TBBPA would elevate BPA concentrations in female and male mice and that this effect would be greatest in serum and in estrogen-binding reproductive tissues. We hypothesized that the actions of TBBPA would be additive with those of triclosan, consistent with evidence that triclosan also inhibits activity of conjugating enzymes ([@c40]; [@c87]). We tested these hypotheses by comparing the impact of TBBPA injection, either alone or in combination with triclosan, on concentrations of ${}^{14}C - \text{BPA}$ in serum and tissues. We also hypothesized that TBBPA could elevate endogenous levels of E2, the most potent natural estrogen ([@c47]), and tested this hypothesis by measuring the impact of TBBPA injection on urinary E2.

Methods {#s2}
=======

Animals and Housing {#s2.1}
-------------------

Female ($30.5 \pm 2.5\; g$) and male ($40.2 \pm 3.6\; g$) CF-1 mice aged 3--4 mo were obtained from Charles River. To standardize timing within the estrous cycle at an easily detected point where estrogen levels are moderate and relatively stable ([@c57]), we selected diestrous females for use in experiments. These females were identified from a colony of mice with regular estrous cycles by vaginal cytology using published procedures ([@c12]). Animals were housed in polypropylene cages measuring $28\;{cm} \times 16\;{cm} \times 11\;{cm}$ ($l \times w \times h$) with *ad libitum* access to food (Teklad 8640 Certified Rodent Chow; Harlan Teklad) and water, except where otherwise stated. The colony was maintained at 21°C with a reversed 14 h light:10 h darkness cycle. All animals were treated humanely and with regard for alleviation of suffering. All procedures adhered to the standards of the Canadian Council on Animal Care and were approved by the Animal Research Ethics Board of McMaster University (Protocol 14-02-03).

Chemicals and Materials {#s2.2}
-----------------------

Triclosan \[5-chloro-2-(2,4-dichlorophenoxy)phenol, $\geq 97\%$ purity\], 3,3′,5,5′-TBBPA \[4,4′-isopropylidenebis(2,6-dibromophenol), $\geq 97\%$ purity\], $17\beta - E2$ ($\geq 98\%$ purity), and creatinine standards were obtained from Sigma-Aldrich. ${}^{14}C - \text{BPA}$ {$\left\lbrack {\text{ring} - \left\lbrack {{}^{14}C} \right\rbrack\left( U \right)} \right\rbrack - \text{BPA}$, in ethanol, $0.1\,\text{mCi}/{mL}$, $106\,\text{mCi}/\text{mmol}$} was obtained from Moravek Biochemicals. SOLVABLE solubilization cocktail, Ultima Gold scintillation cocktail, and $8 - {mL}$ midi-vial scintillation vials were obtained from PerkinElmer. E2 antibodies and horseradish peroxidase (HRP) conjugates were obtained from the Department of Population Health and Reproduction at the University of California, Davis, CA.

Experimental Design and Dosing {#s2.3}
------------------------------

This research followed procedures previously published by this laboratory ([@c72], [@c71]). In brief, mice were weighed, individually housed, and each given a dietary supplement of $1\; g$ peanut butter. Approximately 14--16 h later at the onset of darkness on the following day, animals were randomly assigned to treatment conditions involving a single subcutaneous (sc) injection of TBBPA and/or triclosan dissolved in $0.05\;{mL}$ peanut oil. In experiment 1, males and diestrous females received vehicle or 1, 3, 9, or $27\;{mg}$ TBBPA ($n = 7\,\text{per}\,\text{dose}$). In experiment 2, males ($n = 6\,\text{per}\,\text{dose}$) and diestrous females ($n = 7\,\text{per}\,\text{dose}$) received a single sc injection of vehicle, $0.33\;{mg}$ TBBPA, $0.33\;{mg}$ triclosan, or $0.33\;{mg}\,\text{TBBPA} + 0.33\;{mg}\,\text{triclosan}$. [Table 1](#t1){ref-type="table"} provides TBBPA and triclosan doses in milligrams/kilogram for each treatment condition. At 30 min after injection, each animal was given a dietary supplement of $50\;\mu g/{kg}$ ${}^{14}C - \text{BPA}$ in $0.2\; g$ peanut butter. Food, water, and bedding were removed to prevent contamination of the ${}^{14}C - \text{BPA}$ treatment. At 1 h after ${}^{14}C - \text{BPA}$ administration, each animal was anesthetized with isoflurane, and blood was collected via cardiac puncture. Each animal was perfused with $20\;{mL}$ phosphate-buffered saline (PBS), and tissues were collected in preweighed scintillation vials. Tissue samples taken included the heart, lung, superficial adductor muscle from the hind leg, abdominal adipose, liver, and a cross-section of the kidney encompassing both the medulla and the cortex. Male reproductive tissues taken included one testis, one epididymis, one vesicular-coagulating (VC) gland, and one preputial gland. Female reproductive tissues taken included the whole uterus and both ovaries. Vials were reweighed following tissue collection to determine the sample wet mass; no significant changes in tissue weights were observed (data not shown).

###### 

Mean ($\pm \text{SD}$) TBBPA and triclosan doses in milligrams/kilogram for each treatment condition.

Table 1 lists experiment numbers in the first column; the corresponding n value, the BPA dose in micrograms per kilogram, TBBPA dose in milligrams, TBBPA dose in milligrams per kilogram, triclosan dose in milligram, and triclosan dose in milligrams per kilogram are listed in the other columns.

                 $n$   BPA dose ($\mu g/{kg}$)   TBBPA dose (mg)    TBBPA dose (mg/kg)  Triclosan dose (mg)    Triclosan dose (mg/kg)
  -------------- ----- ------------------------- ----------------- -------------------- --------------------- ------------------------
  Experiment 1                                                                                                            
   Females       7     50                        0                    $0.0 \pm 0.0$                                       
                 7     50                        1                    $32.7 \pm 2.2$                                      
                 7     50                        3                    $95.5 \pm 4.8$                                      
                 7     50                        9                   $291.3 \pm 22.2$                                     
                 7     50                        27                  $860.8 \pm 67.2$                                     
   Males         7     50                        0                    $0.0 \pm 0.0$                                       
                 7     50                        1                    $24.6 \pm 1.4$                                      
                 7     50                        3                    $76.7 \pm 1.9$                                      
                 7     50                        9                   $221.5 \pm 9.6$                                      
                 7     50                        27                  $686.4 \pm 26.5$                                     
  Experiment 2                                                                                                            
   Females       7     50                        0                    $0.0 \pm 0.0$     0                          $0.0 \pm 0.0$
                 7     50                        0                    $0.0 \pm 0.0$     0.33                       $11.4 \pm 0.6$
                 7     50                        0.33                 $10.9 \pm 0.6$    0                          $0.0 \pm 0.0$
                 7     50                        0.33                 $10.8 \pm 0.8$    0.33                       $10.8 \pm 0.8$
   Males         6     50                        0                    $0.0 \pm 0.0$     0                          $0.0 \pm 0.0$
                 6     50                        0                    $0.0 \pm 0.0$     0.33                       $8.4 \pm 0.6$
                 6     50                        0.33                 $9.6 \pm 0.5$     0                          $0.0 \pm 0.0$
                 6     50                        0.33                 $8.0 \pm 0.5$     0.33                       $8.0 \pm 0.5$

Note: BPA, bisphenol A; $n$, number of animals; SD, standard deviation; TBBPA, tetrabromobisphenol A.

In experiment 3, mice were weighed and were individually placed in a Plexiglas apparatus measuring $21\;{cm} \times 15\;{cm} \times 13\;{cm}$ ($l \times w \times h$) with a wire-mesh grid floor raised approximately $1\;{cm}$ above a Teflon-coated stainless-steel surface covered with wax paper. Animals acclimated to the novel cages for 3 d before the start of the experiment. At the onset of darkness on the fourth day, males and diestrous females received a sc injection of vehicle or $1\;{mg}$ TBBPA (corresponding to $33.8 \pm 3.7\;{mg}$ TBBPA/kg for females and $23.4 \pm 2.4\;{mg}$ TBBPA/kg for males) dissolved in $0.05\;{mL}$ peanut oil ($n = 15\,\text{per}\,\text{dose}$). Urine was collected noninvasively at 2, 4, 6, 8, 10, and 12 h postinjection. All urine samples were placed into labeled vials and frozen at $- 20{^\circ}C$ at the time of collection.

We administered triclosan and TBBPA via sc injection to mimic dermal absorption of triclosan from personal care products ([@c24]; [@c74]) and free (unreacted) TBBPA from dust and consumer products ([@c2]; [@c46]). However, percutaneous penetration is incomplete compared with sc injection; $\leq 70\%$ of dermally applied TBBPA is absorbed through rat skin ([@c46]), and $\leq 85\%$ of dermally applied triclosan is absorbed through mouse skin ([@c24]). We administered ${}^{14}C - \text{BPA}$ in a dietary supplement to mimic ingestion of BPA from dust, food, and beverages, which accounts for approximately 85--95% of total exposure in adults ([@c22]). Dietary BPA exposure leads to less-efficient first-pass hepatic metabolism and to higher serum BPA concentrations than oral bolus ([@c81]). The 30-min latency between TBBPA and ${}^{14}C - \text{BPA}$ administration and the 1-h latency between ${}^{14}C - \text{BPA}$ treatment and tissue collection were chosen based on an effective paradigm used in previous studies ([@c72], [@c71]). We selected $1–27\;{mg}$ doses of TBBPA in experiment 1 to establish the impact of a wide range of TBBPA exposures on tissue concentrations of ${}^{14}C - \text{BPA}$. To investigate potential additive effects of TBBPA and triclosan in experiment 2, we selected doses of $0.33\;{mg}$ so that the quantity of either substance was below the lowest effective dose of triclosan ($0.6\;{mg}$) required to elevate ${}^{14}C - \text{BPA}$ concentrations ([@c72]). When both substances were given concurrently, the combined quantity ($0.66\;{mg}$) was greater than the lowest effective dose of triclosan used previously ([@c72]). We selected $1\;{mg}$ TBBPA for experiment 3 because this dose was sufficient to modulate ${}^{14}C - \text{BPA}$ concentrations in experiment 1. We measured urinary E2 because there are very low concentrations of estrogen conjugates in mouse urine ([@c62]), whereas unconjugated E2 is abundant in urine and reflects systemic trends ([@c17], [@c18]; [@c62]; [@c84]. [@c85]).

Blood and Tissue Processing for Liquid Scintillation Counting {#s2.4}
-------------------------------------------------------------

Blood and tissue samples were processed for liquid scintillation counting following previously published procedures ([@c19]; [@c72], [@c71]; [@c70]). Blood samples were centrifuged at $1,500 \times g$ for 10 min, and $10\;\mu L$ serum was added to a scintillation vial containing $5\;{mL}$ Ultima Gold scintillation cocktail. Tissue samples were solubilized by adding $1\;{mL}$ SOLVABLE tissue solubilizer to each vial and placing the vials in a 50°C water bath for 4--5 h until completely dissolved. Following the addition of $5\;{mL}$ Ultima Gold, the vials were agitated to promote mixing of the sample with the scintillation cocktail. Each vial was stored in the darkness chamber of a Tri-Carb 2910TR Liquid Scintillation Analyzer (PerkinElmer) for 5 min to eliminate noise in the form of heat and luminescence. Radioactivity was then measured for 5 min per vial. The amount of radioactivity per sample, in disintegrations per minute (dpm), was automatically calculated via QuantaSmart software by subtracting background radiation, which is continually monitored by the scintillation counter. Frequent cleaning and monitoring of all work surfaces and equipment ensured that contamination of samples did not occur. The final dpm measures were then normalized to the weight of the sample wet mass and were reported as equivalent nanograms BPA/gram tissue or nanograms BPA/milliliter serum.

Measurement of Urinary E2 {#s2.5}
-------------------------

Full procedures and validations for enzyme immunoassays for mouse urine have been reported previously ([@c62]). Cross-reactivities for anti-E2 are as follows: E2, 100%; estrone, 3.3%; progesterone, 0.8%; testosterone, 1.0%; androstenedione, 1.0%, and all other measured steroids, $< 0.1\%$. Urinary E2 levels were considered with and without adjustment for urinary creatinine, which corrects for differential hydration and urinary concentration among animals, and were reported as nanograms E2/milligram creatinine and nanograms E2/milliliter urine, respectively.

Statistical Analyses {#s2.6}
--------------------

All statistical analyses were performed using the R software environment (R Core Team). A comparison-wise error rate of $\alpha < 0.05$ was employed for all tests. Differences between treatments in experiment 1 were analyzed using univariate analysis of variance (ANOVA) for each tissue, with Holm-Bonferroni adjustments to correct for the number of tissues ([@c34]). Observation of significant effects in ANOVA was followed by pairwise Newman-Keuls multiple comparisons. Differences between treatments in reproductive tissues and in serum of animals in experiment 2 were analyzed using Student's *t*-test. Differences between urinary E2 concentrations of animals in experiment 3 were analyzed by factorial ANOVA comparing the effects of treatment and collection time point (repeated measures). Significant main effects or interactions in ANOVA were followed by pairwise Newman-Keuls multiple comparisons of treatment at each collection time point. Data from each experiment for individual animals are provided in Tables S1--S6.

Results {#s3}
=======

Experiment 1: Measurement of ${}^{14}\mathbf{C} - \mathbf{BPA}$ in Mice Given TBBPA {#s3.1}
-----------------------------------------------------------------------------------

This experiment was designed to determine the impact of TBBPA on the distribution of BPA. Radioactivity was measured in tissues and serum of diestrous females ([Figure 1](#f1){ref-type="fig"}; see also Table S1) and of males ([Figure 2](#f2){ref-type="fig"}; see also Table S2) that received a sc injection of TBBPA followed by a dietary supplement of ${}^{14}C - \text{BPA}$. Concentrations of ${}^{14}C - \text{BPA}$ in the liver and kidney are reported in [Table 2](#t2){ref-type="table"}. Pretreatment with TBBPA induced a dose-dependent increase in concentrations of ${}^{14}C - \text{BPA}$ in serum and in most tissues of both sexes.

![Mean ($+ \text{SE}$) concentration of ${}^{14}C -$bisphenol A (BPA) in the heart, lung, muscle, adipose, uterus, ovaries, and serum of diestrous females following subcutaneous (sc) injection of vehicle, 1, 3, 9, or $27\;{mg}$ tetrabromobisphenol A (TBBPA) and subsequent dietary administration of $50\;\mu g/{kg}$ ${}^{14}C - \text{BPA}$ ($n = 7\,\text{per}\,\text{dose}$). Difference from vehicle treatment in the same tissue: \*\*$p < 0.01$; +$p < 0.001$. See Table S1 for individual animal data.](EHP1329_f1){#f1}

![Mean ($+ \text{SE}$) concentration of ${}^{14}C -$bisphenol A (BPA) in the heart, lung, muscle, adipose, testis, epididymis, vesicular-coagulating (VC) gland, preputial gland, and serum of males following subcutaneous (sc) injection of vehicle, 1, 3, 9, or $27\;{mg}$ tetrabromobisphenol A (TBBPA) and subsequent dietary administration of $50\;\mu g/{kg}$ ${}^{14}C - \text{BPA}$ ($n = 7\,\text{per}\,\text{dose}$). Difference from vehicle treatment in the same tissue: \*$p < 0.05$; \*\*$p < 0.01$; +$p < 0.001$. See Table S2 for individual animal data.](EHP1329_f2){#f2}

###### 

Mean ($\pm \text{SE}$) concentration of ${}^{14}C - \text{BPA}$ in the liver and kidney of diestrous females and males following subcutaneous injection of TBBPA and/or triclosan and subsequent dietary administration of $50\;\mu g/{kg}$ ${}^{14}C - \text{BPA}$.

Table 2 lists experiment numbers in the first column; the corresponding TBBPA dose in milligrams, triclosan dose in milligrams, concentration in liver in nanograms BPA per gram, and concentration in kidney in nanograms BPA per gram are listed in the other columns.

                 TBBPA dose (mg)   Triclosan dose (mg)   Liver (ng BPA/g)   Kidney (ng BPA/g)
  -------------- ----------------- --------------------- ------------------ ---------------------
  Experiment 1                                                               
   Females       Vehicle                                 $23.9 \pm 4.0$     $17.6 \pm 4.3$
                 1                                       $23.4 \pm 5.1$     $38.5 \pm 7.4$
                 3                                       $36.2 \pm 5.7$     $70.4 \pm 11.7$^‡^
                 9                                       $14.7 \pm 2.4$     $48.2 \pm 8.3$\*
                 27                                      $16.7 \pm 2.7$     $77.4 \pm 8.9$^‡^
   Males         Vehicle                                 $39.8 \pm 8.3$     $76.0 \pm 6.9$
                 1                                       $70.2 \pm 8.4$\*   $184.5 \pm 25.1$^†^
                 3                                       $51.3 \pm 8.5$     $193.5 \pm 21.5$^†^
                 9                                       $47.7 \pm 6.8$     $265.3 \pm 31.1$^‡^
                 27                                      $27.2 \pm 3.7$     $164.0 \pm 27.5$\*
  Experiment 2                                                               
   Females       Vehicle                                 $25.9 \pm 2.3$     $15.3 \pm 2.9$
                 0                 0.33                  $20.8 \pm 2.9$     $14.0 \pm 1.8$
                 0.33              0                     $24.7 \pm 2.4$     $16.7 \pm 3.4$
                 0.33              0.33                  $38.2 \pm 5.3$     $19.5 \pm 1.4$
   Males         Vehicle                                 $39.1 \pm 4.4$     $86.2 \pm 12.0$
                 0                 0.33                  $43.7 \pm 2.7$     $114.6 \pm 9.0$
                 0.33              0                     $38.6 \pm 3.8$     $106.1 \pm 24.9$
                 0.33              0.33                  $45.2 \pm 4.2$     $119.6 \pm 20.1$

Note: Significance marks indicate differences from vehicle treatment in the same tissue. BPA, bisphenol A; $n$, number of animals; SD, standard deviation; TBBPA, tetrabromobisphenol A.

\* $p < 0.05$. ^†^ $p < 0.01$. ^‡^$p < 0.001$.

Comparisons were made among the five treatments for each of nine tissues in females. ANOVA followed by Holm-Bonferroni correction produced significant effects of treatment for the heart, $F\left( 4,30 \right) = 12.47$, $p < 0.001$; lung, $F\left( 4,30 \right) = 11.14$, $p < 0.001$; muscle, $F\left( 4,30 \right) = 4.23$, $p = 0.024$; uterus, $F\left( 4,30 \right) = 11.92$, $p < 0.001$; ovary, $F\left( 4,30 \right) = 16.97$, $p < 0.001$; kidney, $F\left( 4,30 \right) = 8.19$, $p < 0.001$; and serum, $F\left( 4,30 \right) = 20.41$, $p < 0.001$. Multiple comparisons revealed that the vehicle-treated group differed from the 3-, 9-, and $27 - {mg}$ groups for the heart, lung, uterus, ovaries, kidney, and serum. The vehicle-treated group also differed from the $27 - {mg}$ group for muscle.

Comparisons were made among the five treatments for each of eleven tissues in males. ANOVA followed by Holm-Bonferroni correction produced significant effects of treatment for the heart, $F\left( 4,30 \right) = 8.35$, $p < 0.001$; lung, $F\left( 4,30 \right) = 7.31$, $p = 0.002$; testis, $F\left( 4,30 \right) = 11.13$, $p < 0.001$; epididymis, $F\left( 4,30 \right) = 13.76$, $p < 0.001$; VC gland, $F\left( 4,30 \right) = 4.43$, $p = 0.020$; preputial gland, $F\left( 4,30 \right) = 6.98$, $p = 0.002$; liver, $F\left( 4,30 \right) = 4.61$, $p = 0.020$; kidney, $F\left( 4,30 \right) = 8.06$, $p = 0.001$; and serum, $F\left( 4,30 \right) = 18.32$, $p < 0.001$. Multiple comparisons revealed that the vehicle-treated group differed from the 1-, 3-, 9-, and $27 - {mg}$ groups for the heart, epididymis, VC gland, kidney, and serum. The vehicle-treated group also differed from the $1 - {mg}$ group for the liver; the 3-, 9-, and $27 - {mg}$ groups for the testis; the 9- and $27 - {mg}$ groups for the lung; and the $27 - {mg}$ group for the preputial gland.

Experiment 2: Measurement of ${}^{14}\mathbf{C} - \mathbf{BPA}$ in Mice Given TBBPA and/or Triclosan {#s3.2}
----------------------------------------------------------------------------------------------------

This experiment was designed to determine whether actions of TBBPA or triclosan on the distribution of BPA would be additive when the two substances were given concurrently. Radioactivity was measured in the tissues of diestrous females ([Figure 3](#f3){ref-type="fig"}, [Table 2](#t2){ref-type="table"}; see also Table S3) and of males ([Figure 4](#f4){ref-type="fig"}, [Table 2](#t2){ref-type="table"}; see also Table S4) that received a sc injection of TBBPA, triclosan, or both followed by a dietary supplement of ${}^{14}C - \text{BPA}$. Triclosan and TBBPA showed a greater impact on ${}^{14}C - \text{BPA}$ concentrations in serum and reproductive tissues when administered concurrently. Tests between treatment conditions in females revealed that the vehicle-treated group differed from the group given $0.33\;{mg}\,\text{TBBPA} + 0.33\;{mg}\,\text{triclosan}$ for the uterus, $t\left( 12 \right) = 4.13$, $p = 0.001$; ovaries, $t\left( 12 \right) = 2.66$, $p = 0.021$; and serum, $t\left( 12 \right) = 4.02$, $p = 0.002$. Tests between treatment conditions in males revealed that the vehicle-treated group differed from the group given $0.33\;{mg}\,\text{TBBPA} + 0.33\;{mg}\,\text{triclosan}$ for the testis, $t\left( 10 \right) = 2.63$, $p = 0.025$; epididymis, $t\left( 10 \right) = 2.96$, $p = 0.014$; and serum, $t\left( 10 \right) = 2.89$, $p = 0.016$.

![Mean ($+ \text{SE}$) concentration of ${}^{14}C -$bisphenol A (BPA) in the heart, lung, muscle, adipose, uterus, ovaries, and serum of diestrous females following subcutaneous (sc) injection of vehicle, $0.33\;{mg}$ triclosan, $0.33\;{mg}$ tetrabromobisphenol A (TBBPA), or $0.33\;{mg}\,\text{triclosan} + 0.33\;{mg}\,\text{TBBPA}$ and subsequent dietary administration of $50\;\mu g/{kg}$ ${}^{14}C - \text{BPA}$ ($n = 7\,\text{per}\,\text{dose}$). Difference from vehicle treatment in the same tissue: \*$p < 0.05$; \*\*$p < 0.01$. See Table S3 for individual animal data.](EHP1329_f3){#f3}

![Mean ($+ \text{SE}$) concentration of ${}^{14}C -$bisphenol A (BPA) in the heart, lung, muscle, adipose, testis, epididymis, vesicular-coagulating (VC) gland, preputial gland, and serum of males following sc injection of vehicle, $0.33\;{mg}$ triclosan, $0.33\;{mg}$ tetrabromobisphenol A (TBBPA), or $0.33\;{mg}\,\text{triclosan} + 0.33\;{mg}\,\text{TBBPA}$ and subsequent dietary administration of $50\;\mu g/{kg}$ ${}^{14}C - \text{BPA}$ ($n = 6\,\text{per}\,\text{dose}$). Difference from vehicle treatment in the same tissue: \*$p < 0.05$. See Table S4 for individual animal data.](EHP1329_f4){#f4}

Experiment 3: Measurement of Urinary E2 in Mice Given TBBPA {#s3.3}
-----------------------------------------------------------

This experiment was designed to determine the impact of TBBPA on endogenous E2. Urinary E2 concentrations of diestrous females ([Figure 5](#f5){ref-type="fig"}; see also Table S5) and of males ([Figure 6](#f6){ref-type="fig"}; see also Table S6) were measured after a sc injection of vehicle or TBBPA. Concentrations of E2 are reported for uncorrected (nanograms E2/milliliter urine) and corrected (nanograms E2/milligram creatinine) measures. In females, ANOVA on uncorrected measures showed a significant main effect of collection time point, $F\left( 5,100 \right) = 17.26$, $p < 0.001$, and a significant interaction, $F\left( 5,100 \right) = 2.62$, $p = 0.029$. ANOVA on creatinine-corrected measures showed significant main effects of treatment, $F\left( 1,20 \right) = 17.12$, $p < 0.001$, and collection time point, $F\left( 5,100 \right) = 6.98$, $p < 0.001$, and a significant interaction, $F\left( 5,100 \right) = 4.04$, $p = 0.002$. Multiple comparisons revealed that the vehicle-treated females differed from the TBBPA-treated females at 8 h after injection for the corrected measures, as well as at 10 and 12 h after injection for both the uncorrected and corrected measures. In males, ANOVA on uncorrected measures showed significant main effects of treatment, $F\left( 1,12 \right) = 8.18$, $p = 0.014$, and collection time point, $F\left( 5,60 \right) = 2.87$, $p = 0.022$, but no significant interaction. ANOVA on corrected measures showed only a significant main effect of collection time point, $F\left( 5,60 \right) = 4.86$, $p < 0.001$. Multiple comparisons revealed that the vehicle-treated males differed from the TBBPA-treated males at 2 and 4 h after injection for both the uncorrected and corrected measures, as well as at 10 h after injection for the uncorrected measures.

![Mean ($+ \text{SE}$) concentration of urinary E2, expressed as nanograms $17\beta - \text{estradiol}$ (E2)/milliliter urine and nanograms E2/milligram creatinine, following subcutaneous (sc) injection of vehicle or $1\;{mg}$ tetrabromobisphenol A (TBBPA) in diestrous females ($n = 15\,\text{per}\,\text{dose}$). Significant difference from vehicle treatment at the same time point: \*$p < 0.05$; \*\*$p < 0.01$; +$p < 0.001$. See Table S5 for individual animal data.](EHP1329_f5){#f5}

![Mean ($+ \text{SE}$) concentration of urinary $17\beta - \text{estradiol}$ (E2), expressed as nanograms E2/milliliter urine and nanograms E2/milligram creatinine, following subcutaneous (sc) injection of vehicle or $1\;{mg}$ tetrabromobisphenol A (TBBPA) in males ($n = 15\,\text{per}\,\text{dose}$). Significant difference from vehicle treatment at the same time point: \*$p < 0.05$; \*\*$p < 0.01$; +$p < 0.001$. See Table S6 for individual animal data.](EHP1329_f6){#f6}

Discussion {#s4}
==========

These data show that TBBPA greatly magnifies concentrations of BPA in serum and tissues and that it elevates urinary concentrations of E2. When animals received an oral dose of ${}^{14}C - \text{BPA}$, radioactivity was greater in serum, reproductive tissues, and elsewhere in female and male mice that were pretreated with $1–27\;{mg}$ TBBPA. Radioactivity was also greater in serum and reproductive tissues of mice given $0.33\;{mg}\,\text{TBBPA} + 0.33\;{mg}\,\text{triclosan}$. Urinary E2 concentrations were elevated in animals given $1\;{mg}$ TBBPA. Our novel findings that TBBPA modulates E2 and BPA concentrations underscore a concern ([@c68]) that molecular modeling and *in vitro* studies may not address biological activity *in vivo*.

There are several potential mechanisms through which TBBPA, triclosan, BPA, and E2 could interact. These include direct actions at ER, transport proteins in blood, and enzymes involved in steroid synthesis and metabolism. There is conflicting evidence regarding direct binding to ER of TBBPA ([@c52]; [@c54]; [@c61]; [@c83]) and triclosan ([@c26]; [@c32]; [@c82]). Insofar as there is such binding, actions of TBBPA or triclosan would be competitive with binding of ${}^{14}C - \text{BPA}$, producing an opposing effect to that observed in experiments 1 and 2. Similarly, competition for transport proteins in blood would presumably reduce ${}^{14}C - \text{BPA}$ concentrations in serum and tissues. Our findings in experiments 1 and 2 are much more consistent with competition among TBBPA, triclosan, and ${}^{14}C - \text{BPA}$ for metabolic enzymes. Enzymes of particular interest are those involved in phase II metabolism, including UGT and SULT ([@c21]; [@c91]). The major metabolite of BPA in rodents is the monoglucuronide conjugate resulting from interaction with hepatic UGT 2B1 and potentially other isoforms ([@c38]; [@c49]; [@c96]; [@c97]). Other metabolites of BPA in rodents include the monosulfate conjugate resulting from interaction with SULT 1A1 ([@c95]; [@c97]), as well as the diglucuronide ([@c97]), disulfate ([@c95]), and glucuronide/sulfate ([@c37]) diconjugates.

Sulfate and glucuronide conjugates of TBBPA ([@c9]) and triclosan ([@c24]) have also been observed in rodents. TBBPA can inhibit the activity of SULT 1E1 and SULT 1A1 ([@c28]; [@c29]; [@c31]; [@c43]) and can reduce the expression of genes in the liver that encode SULT 1E1 and SULT 2A1 ([@c78]). Triclosan can inhibit sulfonation and glucuronidation of BPA in human liver fractions ([@c87]).

Our findings in experiment 3 can be explained by competition between TBBPA and E2 for metabolic enzymes. In addition to phase II metabolism (described above), phase I metabolism involving CYP and $17\beta - \text{HSD}$ is important for estrogen metabolism ([@c21]; [@c91]). TBBPA can inhibit CYP 2C9 and CYP 3A4 activity ([@c3]) and $17\beta - \text{HSD}4$ activity ([@c65]) in human liver fractions. TBBPA can reduce expression of genes in the liver that encode $17\beta - \text{HSD}$, but it can increase expression of genes that encode certain CYP isoforms ([@c78]). Our findings in experiment 3 can also be explained by actions of TBBPA on enzymes involved in steroid synthesis. One study found that TBBPA up-regulates aromatase expression and activity in human choriocarcinoma cells for up to 72 h *in vitro* ([@c35]). The latency of TBBPA action on E2, up to 8--12 h in females, could be attributed to increased E2 biosynthesis.

We found that TBBPA magnified concentrations of ${}^{14}C - \text{BPA}$ in the heart, lung, kidney, and blood serum of mice, as well as in the uterus and ovary of females and in the testis, epididymis, VC gland, and preputial gland of males. The impact of $1–27\;{mg}$ TBBPA on ${}^{14}C - \text{BPA}$ concentrations in tissues and in serum is consistent with that previously shown for $0.6–18\;{mg}$ triclosan ([@c72]), except TBBPA appears to have larger effects. This is particularly evident in males because pretreatment with triclosan elevated ${}^{14}C - \text{BPA}$ concentrations in only the epididymis and blood serum ([@c72]). The greatest impact of TBBPA on ${}^{14}C - \text{BPA}$ concentrations was in the lung, reproductive tissues, kidney, and blood serum. The localization of ${}^{14}C - \text{BPA}$ to the lung and reproductive tissues is consistent with the high expression of $\text{ER}\alpha$ and $\text{ER}\beta$ in these tissues ([@c15]; [@c47]). Of the tissue samples collected, the highest concentrations of ${}^{14}C - \text{BPA}$ were in the liver and in the kidney. This observation is consistent with findings from previous studies of the distribution of BPA at doses ranging from 0.5 to $100,000\;\mu g/{kg}$ ([@c44]; [@c48]; [@c70]). These organs are involved in the metabolism and excretion of ingested BPA, and radioactivity in these tissues does not necessarily reflect tissue deposition of ${}^{14}C - \text{BPA}$. Concentrations of ${}^{14}C - \text{BPA}$ were greater in males than in females in most nonreproductive tissues and in blood serum. In vehicle-treated animals in experiment 1, average ${}^{14}C - \text{BPA}$ concentrations in males were greater than those in females for the heart (394%), lung (230%), muscle (294%), adipose tissue (152%), serum (228%), liver (167%), and kidney (433%). These findings are consistent with the distribution of $100\;\mu g/{kg}$ BPA in certain tissues of male and female rats ([@c48]) and may be explained by differences in BPA metabolism, as shown by sex- and tissue-specific expression of numerous UGT isoforms ([@c11]).

Greater concentrations of urinary E2 following TBBPA administration were most evident in females approximately 8--12 h postinjection but were also observed in males approximately 2--4 h postinjection. This discrepancy in latency between males and females may be influenced by differences in the metabolism of TBBPA, differences in estrogen synthesis, or both. The rate of TBBPA glucuronide production is faster in male rat liver fractions ([@c98]), whereas aromatase expression is greater in the ovaries than in the testes ([@c27]). Taken together, these processes may hasten the influence of TBBPA on E2 concentrations in males but result in greater effects of TBBPA on E2 concentrations in females. Slight but persistent elevations in E2 can lead to adverse reproductive and health outcomes in mammals. In mice, heightened E2 levels can prevent intrauterine blastocyst implantation and cause pregnancy failure ([@c84]). In humans, elevated E2 from hormone-replacement therapy correlates with increased risk of breast, endometrial, and ovarian cancer ([@c59], [@c60], [@c5]).

Data from the 2011--2012 U.S. National Health and Nutrition Examination Survey (NHANES) indicated that 72% of human urine samples contain detectable triclosan concentrations ranging from 2.3 to $3,830\;\mu g/L$ ([@c30]). Although NHANES did not report TBBPA concentrations in urine, TBBPA was detected in 93% of plasma samples and in 89% of urine samples in a study of 140 healthy adults in China ([@c33]). Some published reports have estimated daily TBBPA exposure levels in the range of $3.2 \times 10^{- 7}$ to $1.95 \times 10^{- 4}\,{mg}/{kg}/\text{day}$ ([@c23]; [@c66]; [@c90]). However, these exposure estimates are derived from concentrations of TBBPA in environmental media and may not account for all exposure pathways. Furthermore, interactions among chemicals may influence their distribution, metabolism, and excretion, as indicated by our data. One study suggested that disruption of homeostatic control of TBBPA and estrogen conjugation is unlikely in humans because the doses required to produce uterine tumors in rodents are orders of magnitude greater than exposure estimates in humans ([@c9]). However, our data show clear *in vivo* interaction between TBBPA and triclosan, indicating that it is not appropriate to consider only one chemical in isolation. Inhibition of enzymes involved in estrogen metabolism has been shown for a number of environmental chemicals and their metabolites, including parabens ([@c69]; [@c73]), phthalates ([@c69]), polychlorinated biphenyls ([@c42]; [@c88]), and polyhalogenated aromatic hydrocarbons ([@c43]). Given the potential adverse reproductive and carcinogenic outcomes of persistently elevated estrogenic activity, these findings demonstrate the importance of considering multiple toxicants when determining regulatory exposure limits.

Conclusion {#s5}
==========

These data demonstrate that concurrent exposure to TBBPA elevates concentrations of dietary BPA in reproductive and other tissues. TBBPA and triclosan have additive effects in their capacity to modulate concentrations of BPA. TBBPA also elevates measures of urinary E2 in mice. These effects are consistent with competition among these synthetic chemicals and endogenous steroids for conjugating enzymes. These results indicate that TBBPA and triclosan, both of which have negligible direct effects on ER, can have indirect estrogenic effects.
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